66 related articles for article (PubMed ID: 38741006)
1. A CRISPR-Cas Cure for HIV/AIDS.
Hussein M; Molina MA; Berkhout B; Herrera-Carrillo E
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675077
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 mRNA knockdown with CRISPR/CAS9 enhances neurocognitive function.
McLaurin KA; Li H; Khalili K; Mactutus CF; Booze RM
J Neurovirol; 2024 Feb; 30(1):71-85. PubMed ID: 38355914
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/CAS as a Powerful Tool for Human Immunodeficiency Virus Cure: A Review.
Vasconcelos Komninakis S; Domingues W; Saeed Sanabani S; Angelo Folgosi V; Neves Barbosa I; Casseb J
AIDS Res Hum Retroviruses; 2024 Jun; 40(6):363-375. PubMed ID: 38164106
[TBL] [Abstract][Full Text] [Related]
4. CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice.
Dash PK; Chen C; Kaminski R; Su H; Mancuso P; Sillman B; Zhang C; Liao S; Sravanam S; Liu H; Waight E; Guo L; Mathews S; Sariyer R; Mosley RL; Poluektova LY; Caocci M; Amini S; Gorantla S; Burdo TH; Edagwa B; Gendelman HE; Khalili K
Proc Natl Acad Sci U S A; 2023 May; 120(19):e2217887120. PubMed ID: 37126704
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant.
Hsu J; Van Besien K; Glesby MJ; Pahwa S; Coletti A; Warshaw MG; Petz L; Moore TB; Chen YH; Pallikkuth S; Dhummakupt A; Cortado R; Golner A; Bone F; Baldo M; Riches M; Mellors JW; Tobin NH; Browning R; Persaud D; Bryson Y;
Cell; 2023 Mar; 186(6):1115-1126.e8. PubMed ID: 36931242
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.
Swamy MN; Wu H; Shankar P
Adv Drug Deliv Rev; 2016 Aug; 103():174-186. PubMed ID: 27013255
[TBL] [Abstract][Full Text] [Related]
7. Gaining momentum: stem cell therapies for HIV cure.
Buck AM; LaFranchi BH; Henrich TJ
Curr Opin HIV AIDS; 2024 Jul; 19(4):194-200. PubMed ID: 38686850
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide CRISPR/Cas9 screen reveals JunB downmodulation of HIV co-receptor CXCR4.
Schulze WJ; Gregory DA; Johnson MC; Lange MJ
Front Microbiol; 2024; 15():1342444. PubMed ID: 38835488
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 proviral DNA in purified peripheral blood CD34
Tassaneetrithep B; Phuphuakrat A; Pasomsub E; Bhukhai K; Wongkummool W; Priengprom T; Khamaikawin W; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Heliyon; 2024 Feb; 10(4):e26613. PubMed ID: 38434025
[TBL] [Abstract][Full Text] [Related]
11. In vivo selection of anti-HIV-1 gene-modified human hematopoietic stem/progenitor cells to enhance engraftment and HIV-1 inhibition.
Guo Q; Zhang J; Parikh K; Brinkley A; Lin S; Zakarian C; Pernet O; Shimizu S; Khamaikawin W; Hacke K; Kasahara N; An DS
Mol Ther; 2024 Feb; 32(2):384-394. PubMed ID: 38087779
[TBL] [Abstract][Full Text] [Related]
12. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells.
Tsuchida CA; Brandes N; Bueno R; Trinidad M; Mazumder T; Yu B; Hwang B; Chang C; Liu J; Sun Y; Hopkins CR; Parker KR; Qi Y; Hofman L; Satpathy AT; Stadtmauer EA; Cate JHD; Eyquem J; Fraietta JA; June CH; Chang HY; Ye CJ; Doudna JA
Cell; 2023 Oct; 186(21):4567-4582.e20. PubMed ID: 37794590
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Cas9 protein production in an endotoxin-free system and evaluation with editing the BCL11A gene in human cells.
Singpant P; Tubsuwan A; Sakdee S; Ketterman AJ; Jearawiriyapaisarn N; Kurita R; Nakamura Y; Songdej D; Tangprasittipap A; Bhukhai K; Chiangjong W; Hongeng S; Saisawang C
Protein Expr Purif; 2023 Oct; 210():106313. PubMed ID: 37276914
[TBL] [Abstract][Full Text] [Related]
14. Validation of Promoters and Codon Optimization on CRISPR/Cas9-Engineered Jurkat Cells Stably Expressing αRep4E3 for Interfering with HIV-1 Replication.
Chupradit K; Sornsuwan K; Saiprayong K; Wattanapanitch M; Tayapiwatana C
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499376
[TBL] [Abstract][Full Text] [Related]
15. The reservoir of latent HIV.
Chen J; Zhou T; Zhang Y; Luo S; Chen H; Chen D; Li C; Li W
Front Cell Infect Microbiol; 2022; 12():945956. PubMed ID: 35967854
[TBL] [Abstract][Full Text] [Related]
16. RISC-y Business: Limitations of Short Hairpin RNA-Mediated Gene Silencing in the Brain and a Discussion of CRISPR/Cas-Based Alternatives.
Goel K; Ploski JE
Front Mol Neurosci; 2022; 15():914430. PubMed ID: 35959108
[TBL] [Abstract][Full Text] [Related]
17. Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV.
Freen-van Heeren JJ
BioTech (Basel); 2022 Jul; 11(3):. PubMed ID: 35892930
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice.
Li S; Holguin L; Burnett JC
Mol Ther Methods Clin Dev; 2022 Mar; 24():321-331. PubMed ID: 35229006
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
